PMID- 32846789
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 34
DP  - 2020 Aug 21
TI  - A meta-analysis comparing stereotactic body radiotherapy vs conventional 
      radiotherapy in inoperable stage I non-small cell lung cancer.
PG  - e21715
LID - 10.1097/MD.0000000000021715 [doi]
LID - e21715
AB  - BACKGROUND: Stereotactic body radiotherapy (SBRT) superseded conventional 
      radiotherapy (CRT) for the treatment of patients with inoperable early stage 
      non-small cell lung cancer (NSCLC) over a decade ago. However, the direct 
      comparisons of the outcomes of SBRT and CRT remain controversial. This 
      meta-analysis was performed to compare the survival and safety of SBRT and CRT in 
      patients with inoperable stage I NSCLC. METHODS: We systematically searched the 
      Cochrane Library, Embase, PubMed, Web of Science, Ovid MEDLINE, ScienceDirect, 
      Scopus and Google Scholar for relevant articles. Overall survival (OS), 
      progression-free survival (PFS), lung cancer-specific survival (LCSS), local 
      control rate (LCR) and adverse effects (AEs) were the primary outcomes. RESULTS: 
      We identified 11,110 articles, 17 of which were eventually included in this 
      study; these 17 articles had 17,973 patients (SBRT: 7395; CRT: 10,578). Compared 
      to CRT for the treatment of inoperable stage I NSCLC, SBRT had superior survival 
      in terms of OS (hazard ratio [HR]: 0.66, 95% confidence interval [CI]: 0.62-0.70, 
      P < .00001), LCSS (HR: 0.42 [0.35-0.50], P < .00001), and PFS (HR: 0.34 
      [0.25-0.48], P < .00001). The 4-year OS rate (OSR); 4-year LCSS rate (LCSSR); 
      3-year local control rate (LCR); 5-year PFS rate (PFSR) with SBRT were all higher 
      than those with CRT. With regard to all-grade AEs, the SBRT group had a 
      significantly lower rate of dyspnea, esophagitis and radiation pneumonitis; no 
      significant difference was found in grade 3-5 AEs (risk ratio [RR]: 0.68 
      [0.30-1.53], P = .35). CONCLUSIONS: With better survival and a lower rate of 
      dyspnea, esophagitis and radiation pneumonitis than CRT, SBRT appears to be more 
      suitable for patients with inoperable stage I NSCLC.
FAU - Li, Can
AU  - Li C
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University.
AD  - Jiangxi medical college, Nanchang University.
FAU - Wang, Li
AU  - Wang L
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University.
AD  - Jiangxi medical college, Nanchang University.
FAU - Wu, Qian
AU  - Wu Q
AD  - Jiangxi medical college, Nanchang University.
FAU - Zhao, Jiani
AU  - Zhao J
AD  - Jiangxi medical college, Nanchang University.
FAU - Yi, Fengming
AU  - Yi F
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Xu, Jianjun
AU  - Xu J
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University.
FAU - Wei, Yiping
AU  - Wei Y
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University.
FAU - Zhang, Wenxiong
AU  - Zhang W
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Age Factors
MH  - Carcinoma, Non-Small-Cell Lung/mortality/pathology/*radiotherapy
MH  - Humans
MH  - Lung Neoplasms/mortality/pathology/*radiotherapy
MH  - Neoplasm Staging
MH  - Progression-Free Survival
MH  - Proportional Hazards Models
MH  - Radiation Injuries/epidemiology
MH  - Radiosurgery/adverse effects/*methods
MH  - Survival Rate
PMC - PMC7447473
COIS- The authors have no relevant affiliations or financial involvement with any 
      organization or entity with a financial interest in or financial conflict with 
      the subject matter or materials discussed in the manuscript. This includes 
      employment, consultancies, honoraria, stock ownership or options, expert 
      testimony, grants or patents received or pending, or royalties.
EDAT- 2020/08/28 06:00
MHDA- 2020/09/15 06:00
PMCR- 2020/08/21
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2020/08/21 00:00 [pmc-release]
AID - 00005792-202008210-00043 [pii]
AID - MD-D-20-00351 [pii]
AID - 10.1097/MD.0000000000021715 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 21;99(34):e21715. doi: 
      10.1097/MD.0000000000021715.